Orexigen Therapeutics, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 77   

Articles published

OREX 5.67 -0.03 (-0.53%)
price chart
Orexigen Therapeutics, Inc. (NASDAQ: OREX) Upcoming FDA Decision in Early ...
Orexigen Therapeutics, Inc. (NASDAQ: OREX) awaits the approval of their lead candidate, the anti-obesity drug Contrave, also known as NB32.
Traders Favorite: Orexigen Therapeutics, Inc. (NASDAQ:OREX), IGI ...  Market News Call
Related articles »  
Orexigen Therapeutics Inc.: Orexigen Expands NB32 Intellectual Property ...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the U.S. Patent and Trademark Office (PTO) has issued a patent related to NB32, the Company's investigational medication being evaluated for ...
Orexigen Expands NB32 Intellectual Property Portfolio with New US Patent  ag-IP-news Agency
Related articles »  
Orexigen Therapeutics Reports Corporate and Financial Results for the Second ...
SAN DIEGO, Aug. 7, 2014 /PRNewswire/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced corporate and financial results for the second quarter ended June 30, 2014.
Orexigen Therapeutics, Inc. (OREX) Reports In-Line Q2 Loss of 21c/Share  StreetInsider.com (subscription)
Orexigen Therapeutics (OREX) Releases Quarterly Earnings Results, Meets ...  Ticker Report
Related articles »  
Orexigen Therapeutics Misses Second-Quarter Estimates
The substantial increase in revenues is based on the expected payment of $100 million from Takeda Pharmaceutical Company Limited, contingent to the approval of Orexigen's obesity drug NB32. The Food and Drug Administration (FDA) will reveal its ...
Orexigen Therapeutics Reports Wider Q2 Loss as Costs Mount - Analyst Blog  NASDAQ
Related articles »  
Trending Tickers : Orexigen Therapeutics (NASDAQ:OREX), Xilinx Inc ...
Orexigen Therapeutics, Inc. (NASDAQ:OREX) reported a net loss of 21 cents per share in the second quarter of 2014, wider than the year-ago loss of 19 cents.
Small Cap Obesity Stock Orexigen Therapeutics (OREX) Awaits Its Fate (ARNA ...
Small cap biotech Orexigen Therapeutics, Inc (OREX) is developing an obesity drug with a FDA Prescription Drug User Fee Act (PDUFA) action date set for September 11 plus a look at the so-so performance of obesity stocks Arena Pharmaceuticals, Inc ...
Investors Watch List : Orexigen Therapeutics (NASDAQ:OREX), Dollar General ...
Orexigen Therapeutics, Inc. (NASDAQ:OREX) on Aug. 7 announced corporate and financial results for the second quarter ended June 30, 2014.
Investors Alert: Glu Mobile Inc.(NASDAQ:GLUU), Orexigen Therapeutics, Inc ...  Market News Call
Stocks to Watch - Orexigen Therapeutics, Inc. (NASDAQ:OREX), Southwest ...  Techsonian (press release)
Related articles »  
Stocks to Watch: Orexigen Therapeutics, Inc. (OREX), National Bank of Greece ...
Manhattan, NY- August 23, 2014 - (Techsonian) - Orexigen Therapeutics, Inc. (NASDAQ:OREX) released corporate and financial outcomes for the second quarter ended June 30, 2014.
Related articles »  
Hot News: Orexigen Therapeutics (NASDAQ:OREX), Banco Santander (NYSE ...
On 8 AUG Orexigen Therapeutics, Inc. (NASDAQ:OREX) missed analysts' revenue estimates for the second quarter of its fiscal year 2014 (2QFY15, which ended on June 30), while earnings were in line.
Stocks Alert- Orexigen Therapeutics, Inc. (OREX), Q Arena Pharmaceuticals, Inc ...
Stamford, Connecticut - 18th Aug 2014- (Techsonian) - Orexigen Therapeutics, Inc. (NASDAQ:OREX), a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.